-5%
Finerenone is prescribed to lower the risk of sustained declines in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and heart failure hospitalizations in adults with chronic kidney disease (CKD) related to type 2 diabetes (T2D).
Finerenone is a nonsteroidal mineralocorticoid receptor (MR) antagonist that selectively targets MR, which is activated by aldosterone and cortisol and influences gene expression. By blocking MR-mediated sodium reabsorption and MR overactivation in tissues like the kidneys, heart, and blood vessels, Finerenone helps to counteract fibrosis and inflammation. It has high potency and selectivity for MR, with minimal interaction with other steroid receptors. When used, Finerenone has been shown to reduce systolic blood pressure by 3 mmHg and diastolic blood pressure by 1-2 mmHg. The drug does not prolong the QT interval even at doses up to four times the maximum recommended amount. After oral administration, Finerenone is fully absorbed but has a 44% absolute bioavailability. Peak plasma levels are reached within 0.5 to 1.25 hours. Finerenone’s exposure increases with dose, reaching a steady state in about 2 days. It has a volume of distribution of 52.6 L and is 92% bound to plasma proteins. Its half-life is approximately 2 to 3 hours, and it is primarily metabolized by CYP3A4 with about 80% of the dose excreted in the urine.